White Paper: Oracle Argus Release 8.2.2 – What’s New?

Aug 17, 2020 | NEWS

Scroll down to request the white paper “Oracle Argus Release 8.2.2 – What’s New?”

Oracle Argus is a multivigilance solution for processing, analysing, and reporting adverse event cases originating in pre- and post-market drugs, biologics, vaccines, devices, and combination products. A powerful tool, Argus was designed to solve the pharmaceutical industry’s biggest regulatory challenges.

Oracle Argus allows you to manage adverse event cases more accurately and more efficiently whilst ensuring regulatory compliance and helping Life Sciences companies to satisfy their growing needs.

Oracle Argus is currently used worldwide by a wide range of Life Sciences companies such as:

  • Pharmaceutical
  • Biotech
  • CRO (Contract Research Organisation)
  • Medical device manufacturers

Scalable and efficient, Argus enables the continuous evaluation of the benefit-risk profiles of products throughout clinical development and post-marketing surveillance in accordance with Good Clinical Practice and Good Pharmacovigilance Practice. Argus is a reliable solution that offers proven reporting compliance with regulations and standards at the national and international level.

In July 2020, Oracle released a new version 8.2.2 that addressed new important regulatory compliance requirements, functional enhancements and technology platform currency.

In this white paper we will share the details of the Oracle Argus Release 8.2.2 and analyse the benefits for Life Sciences companies of moving from outdated legacy systems to Argus or upgrading their Argus platform to this new release.

 


Request the white paper “Oracle Argus Release 8.2.2 – What’s New?”

    The undersigned shall give specific consent to the processing of personal data for marketing purposes (namely direct sale, sending of advertising material, market research and commercial communication). *

    The undersigned shall give specific consent to the processing of their personal data for profiling activities. *

    The undersigned shall give specific consent to the processing of their personal data for communicating data to third parties for marketing purposes. *

    By submitting this request, you confirm that you have read the Arithmos privacy policy available here.

    NEWS:

    A letter from our CEO 
    READ ARTICLE
    close-link
    Read a letter from our CEO?